Who Actually Pays for Innovation? The Economic Tradeoffs of Breakthrough Therapies
Who Actually Pays for Innovation? The Economic Tradeoffs of Breakthrough Therapies
Medical innovation is accelerating. Gene therapies promise one-time cures for inherited disorders. Cell-based treatments are reshaping oncology. Highly targeted biologics are transforming rare disease management.
These advances are scientifically remarkable. They are also extraordinarily expensive.
Which raises an uncomfortable but unavoidable question: Who should pay for them?
The Unique Economics of Rare Disease Therapies
Many breakthrough therapies today target rare or ultra-rare conditions. Developing these treatments requires:
Years of research and clinical trials
Highly specialized manufacturing processes
Small patient populations over which to spread R&D costs
Complex regulatory oversight
Unlike widely used small-molecule drugs of the past, these therapies cannot rely on scale to reduce per-patient cost. As a result, price tags in the hundreds of thousands—or even millions—of dollars are becoming more common.
From a scientific standpoint, this trajectory is predictable. From an economic standpoint, it forces difficult tradeoffs.
Individual Responsibility vs. Social Risk Pooling
Insurance, at its core, is a mechanism for spreading risk across a population. Rare diseases are, by definition, low-probability but high-cost events. That is precisely the type of risk insurance was designed to absorb.
If individuals were solely responsible for paying for breakthrough therapies, many would simply go untreated. For most families, a $1–3 million therapy is financially impossible.
On the other hand, distributing these costs across society through private insurance premiums or government programs increases overall healthcare spending and, ultimately, taxes or premium costs.
So the real debate is not whether someone pays—it is how the cost is distributed.
Should society absorb these costs collectively in the name of compassion and shared risk?
Or should there be limits to what the broader system is expected to finance?
These are economic and ethical questions intertwined.
The Value Question
Another layer complicates the discussion: value.
Some gene therapies offer the possibility of lifelong cure after a single administration. When compared to decades of chronic treatment, hospitalizations, and supportive care, the long-term cost may actually be lower—even if the upfront price is staggering.
In pharmacoeconomic terms, a therapy can be cost-effective over a lifetime horizon while still being unaffordable in the short term.
This disconnect between long-term value and short-term budget impact is one of the central challenges in modern healthcare financing.
The Case for Paying Over Time
One promising solution is restructuring how we pay for these therapies.
Instead of requiring full payment upfront, alternative models could include:
Annuity-based payments spread over several years
Outcomes-based contracts, where payment depends on clinical success
Risk-sharing agreements between manufacturers and payers
Portability mechanisms, so payment responsibility can follow a patient between insurers
Paying over time better aligns cost with realized benefit. If a therapy delivers durable outcomes, payment continues. If it fails to meet expectations, financial risk is shared.
This model reflects how society pays for other high-cost assets—homes, infrastructure, capital equipment—rather than demanding immediate full payment.
A System-Level Challenge
Breakthrough therapies expose a fundamental tension in healthcare economics:
Innovation pushes the boundaries of what is medically possible.
Financing systems struggle to keep pace.
If society underpays for innovation, investment may slow, and future cures may never materialize.
If society pays without constraint, premiums and public spending may become unsustainable.
The goal is not to reject innovation nor to ignore cost. It is to design financing systems that recognize both the scientific complexity of modern medicine and the economic realities of shared risk.
What This Means for Pharmacy
Pharmacists increasingly operate at the center of this tension. We see:
The clinical promise of breakthrough therapies
The administrative barriers to access
The budget constraints of payers
The emotional and financial strain on patients
As medicine advances, these conversations will only intensify.
The question is no longer whether breakthrough therapies are worth developing. It is how we, as a society, choose to finance them.
Innovation has a cost. The real policy debate is how that cost should be shared.
